Marketing channel feed

Jason, a triathlete and CoolSculpting user, is one of several actual users featured in Allergan Aesthetics' new DTC effort.

Ab­b­Vie ex­pands use of re­al pa­tients in lat­est Al­ler­gan Aes­thet­ics DTC cam­paign

AbbVie’s Allergan Aesthetics is enlisting real people for the first time in a new campaign for CoolSculpting. Its latest push for the body fat-freezing system includes TV commercials that begin on Monday, along with digital and social media.

In the TV ads, people talk about having children or aging and their bodies changing. The active adults – including a dancer and a triathlete – open up about “trying everything” and the decision to try the aesthetic procedure.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,700+ biopharma pros reading Endpoints daily — and it's free.

As new C. diff treat­ments prep for mar­ket, spe­cial­ists di­vid­ed on 'poop in a pil­l' or small mol­e­cule, study finds

What do physicians think about the emerging market for recurrent C. diff? That depends on who you talk to, especially which specialists you talk to.

Fecal microbiota transplants, or FMT, are favored by gastroenterologists familiar with them, while infectious disease doctors prefer traditional small molecule therapies, according to a recent future market evaluation by Spherix Global Insights. While current FMT involves transplanting healthy stool into a C. diff patient through a colonoscopy, FMT encapsulated microbiome pills that are swallowed – referred to by doctors as “poop in a pill” in Spherix’s interviews – are likely on the way to market.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,700+ biopharma pros reading Endpoints daily — and it's free.

MRx roundup: Ho­log­ic en­lists Sh­eryl Crow for screen­ings; J&J Quick­Fire teams with feds for pub­lic health

Hologic is adding another effort from Grammy-winning musician Sheryl Crow, who’s also a breast cancer survivor, to its most recent marketing efforts. Crow, a long-time Hologic spokesperson, is speaking out to encourage women to schedule annual mammograms. Crow paired with radiologist Arlene Richardson to talk about the importance of health screenings.

The social media effort is built on insights from a recent study commissioned by Hologic that found that only 59% of people who responded were up-to-date. Meanwhile, the top source of information about mammograms? Mom first, followed by their primary care physician.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,700+ biopharma pros reading Endpoints daily — and it's free.

Per­pet­u­al cri­sis? Phar­ma com­mu­ni­ca­tions and pub­lic re­la­tions pros just wait for the next shoe to drop

Welcome to pharma public relations where every day feels like it might be a crisis.

More than three-fourths (76%) of pharma communications leaders expect to face three or more crises this year — compared to less than half (49%) of their peers in other industries, according to new survey from risk intelligence company Crisp. The same 76% also expect that a brand new risk that is yet to be identified will crop up this year, compared to 66% of peers across other industries who worry about the same thing.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,700+ biopharma pros reading Endpoints daily — and it's free.

Emma Walmsley, GSK CEO (Fang Zhe/Xinhua/Alamy Live News)

A long time com­ing: Glax­o­SmithK­line of­fi­cial­ly changes name to GSK

Shorter is better, at least according to GlaxoSmithKline, which officially changed its name on Monday to a simple three letters: GSK.

The news comes weeks ahead of GSK’s anticipated consumer healthcare spinout, though it isn’t strictly linked to the demerger, according to a source with knowledge of the matter. Though GSK first announced the change back in April, it has been in the works for a while, the source said. GSK has often made use of the abbreviation on buildings and in announcements (even its stock ticker is $GSK).

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,700+ biopharma pros reading Endpoints daily — and it's free.

Roche lays out ac­cess am­bi­tions in its ESG strate­gies, in­clud­ing in­no­va­tion and val­ue goals

Roche laid out its ambitions in the social part of its environmental, social and governance (ESG) strategy on Monday centered on access to its drugs and diagnostics.

The Roche inaugural Access to Healthcare investor call follows a general pharma industry trend in ESG. More companies are publishing reports and holding calls to outline climate, societal, diversity, and even pricing goals as investors clamor for details amid surging interest in ESG commitments.

An outdoor mural of a hand with gout uric acid crystals is part of Horizon's latest campaign to raise gout awareness and erase stigma.

Strik­ing mu­rals in US cities high­light Hori­zon and Arthri­tis Foun­da­tion col­lab for gout aware­ness

Gout is the most common form of inflammatory arthritis, but not many people make the connection. That’s why Horizon Therapeutics is partnering with the Arthritis Foundation in a new campaign that includes outdoor murals in cities across the US. In each of the four artworks, the uric acid crystals that build up inside the body with gout are shown as bright green crystals on hands, feet or spine.

The murals include Horizon’s campaign website uncovergout.com where people can see a behind-the-scenes video about the condition and the making of the images, along with more information and patients’ stories about the stigma and misconceptions around gout.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,700+ biopharma pros reading Endpoints daily — and it's free.

BioFron­tera bows bold im­agery web­sites amid Q1 sales gains in der­ma­tol­ogy

Sharks lurking under the skin and grimacing impetigo lesions are the striking images topping BioFrontera’s new and revamped websites for its flagship brands Ameluz and Xepi, respectively.

The skin specialist biopharma’s Ameluz site is its first aimed at patients while the Xepi revamp expands information and resources for both patients and physicians in the now one-stop site.

Ameluz is a gel used in photodynamic therapy along with a specialized lamp to treat actinic keratosis (AK) lesions on the face and scalp. AK, also called solar keratosis, is a type of pre-cancer that if untreated can develop into squamous cell carcinoma. The shark-shaped protrusions appear on the scalp of a man who also has lesions on the new Ameluz page under the headline “When danger lurks below the surface.”

Former NSYNC member Lance Bass is Amgen's new psoriatic arthritis spokesperson

Boy bands and pso­ri­at­ic arthri­tis? NSYNC’s Lance Bass cre­ates new dance for Am­gen about ear­ly signs

NSYNC boy band member Lance Bass didn’t realize his aches and pains weren’t just a byproduct of a busy lifestyle, many years of dancing and of course, aging. Instead, it was psoriatic arthritis.

Now Bass is partnering with Amgen and its anti-inflammatory brand Otezla to help others recognize the signs of psoriatic arthritis. The singer and dancer, whose career began as one of the five boys of NSYNC with popular hit songs and coordinated dance move videos such as “Bye Bye Bye” and “It’s Gonna Be Me,” is translating those moves to a short TikTok-style “Double Take” dance.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,700+ biopharma pros reading Endpoints daily — and it's free.

Marco Taglietti, Scynexis CEO

‘Say no more’ to yeast in­fec­tions: Scynex­is rolls out new Brex­afemme mar­ket­ing — and ral­ly­ing cry

Scynexis is rolling out a new campaign for its Brexafemme yeast infection treatment, but the effort is more than just advertising.

As CEO Marco Taglietti said in wrapping his prepared comments during an earnings call on Thursday, “Let me finish with our new rallying cry — yeast infection, say no more.”

That headline — written as “Yeast infection? Say no more” — appears on Scynexis’ recently launched ad campaign to healthcare providers and will begin rolling out to consumers later this month.